Catalyst Pharmaceuticals (CPRX) Receivables - Net (2019 - 2026)

Catalyst Pharmaceuticals (CPRX) has 8 years of Receivables - Net data on file, last reported at $130.8 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 83.59% year-over-year to $130.8 million; the trailing twelve-month figure through Mar 2026 stood at $130.8 million (up 83.59% YoY), and the FY2025 full-year result was $126.5 million, up 93.17% from the prior year.
• Receivables - Net for Q1 2026 stood at $130.8 million, up from $126.5 million in the prior quarter.
• Across five years, Receivables - Net topped out at $130.8 million in Q1 2026 and bottomed at $9.3 million in Q3 2022.
• The 5-year median for Receivables - Net is $57.2 million (2024), against an average of $56.5 million.
• The widest annual swing landed in 2023, when Receivables - Net soared 414.61%; it then increased 15.2% in 2025.
• A 5-year view of Receivables - Net shows it stood at $10.4 million in 2022, then soared by 412.64% to $53.5 million in 2023, then advanced by 22.35% to $65.5 million in 2024, then jumped by 93.17% to $126.5 million in 2025, then climbed by 3.44% to $130.8 million in 2026.
• The last three Receivables - Net figures came in at $130.8 million (Q1 2026), $126.5 million (Q4 2025), and $106.4 million (Q3 2025), per Business Quant data.

Peer Comparison